First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach

Pharmacokinetic Analysis of a Novel Human EGFRvIII:CD3 Bispecific Antibody in Plasma and Whole Blood Using a High-Resolution Targeted Mass Spectrometry Approach

(2019) Teilo H. Schaller et al.   JOURNAL OF PROTEOME RESEARCH

Bispecific antibodies: a mechanistic review of the pipeline

(2019) Aran F. Labrijn et al.   NATURE REVIEWS DRUG DISCOVERY

A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma

(2018) Patrick C. Gedeon et al.   CLINICAL CANCER RESEARCH

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

(2018) Fabio Conforti et al.   LANCET ONCOLOGY

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

An Update on Immunotherapy for Solid Tumors: A Review

(2018) Toan Pham et al.   ANNALS OF SURGICAL ONCOLOGY

CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response

(2018) Katherine A. Riccione et al.   OncoImmunology

Acute lymphoblastic leukaemia in 2017: Immunotherapy for ALL takes the world by storm

(2017) David T. Teachey et al.   Nature Reviews Clinical Oncology

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection

(2017) Haleh Saber et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Advances and challenges: dendritic cell vaccination strategies for glioblastoma

(2016) Teilo H. Schaller et al.   Expert Review of Vaccines

Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody

(2016) Sherri Dudal et al.   JOURNAL OF IMMUNOTHERAPY

Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013

(2016) Hoon Young Suh et al.   Drug Design Development and Therapy

Advances in Cancer Immunotherapy in Solid Tumors

(2016) Smitha Menon et al.   Cancers

Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development

(2015) Meina Liang et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma

(2015) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma

(2014) Kristen A Batich et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma

(2012) B. D. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety Assessment and Dose Selection for First-in-Human Clinical Trials With Immunomodulatory Monoclonal Antibodies

(2009) PY Muller et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies

(2009) Patrick Y Muller et al.   CURRENT OPINION IN BIOTECHNOLOGY

Toward experimental assessment of receptor occupancy: TGN1412 revisited

(2008) Zoe Waibler et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY